Key clinical point: Ovarian arteries embolization (OAE) improved quality of life (QoL) and lowered rates of subsequent surgery in women who experienced persistent symptoms after uterine arteries embolization (UAE) for uterine fibroids (UF).

Major finding: Less than a fifth of the cohort underwent subsequent hysterectomy. Almost 90.9% of patients who underwent magnetic resonance imaging after 12 months of OAE showed a decrease in uterine volume and complete devascularization of the dominant fibroid tumor. After a mean follow-up of 70 months, 8 of the 10 patients who responded to the QoL questionnaire reported an improvement or stability of symptoms.

Study details: Findings are from a retrospective analysis of 1,300 women treated with UAE for symptomatic UF, of which 18 women underwent a second embolization through one or both ovarian arteries.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Ifergan H et al. Abdom Radiol (NY). 2021 Aug 25. doi: 10.1007/s00261-021-03255-w.

Key clinical point: Ovarian arteries embolization (OAE) improved quality of life (QoL) and lowered rates of subsequent surgery in women who experienced persistent symptoms after uterine arteries embolization (UAE) for uterine fibroids (UF).

Major finding: Less than a fifth of the cohort underwent subsequent hysterectomy. Almost 90.9% of patients who underwent magnetic resonance imaging after 12 months of OAE showed a decrease in uterine volume and complete devascularization of the dominant fibroid tumor. After a mean follow-up of 70 months, 8 of the 10 patients who responded to the QoL questionnaire reported an improvement or stability of symptoms.

Study details: Findings are from a retrospective analysis of 1,300 women treated with UAE for symptomatic UF, of which 18 women underwent a second embolization through one or both ovarian arteries.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Ifergan H et al. Abdom Radiol (NY). 2021 Aug 25. doi: 10.1007/s00261-021-03255-w.

Key clinical point: Ovarian arteries embolization (OAE) improved quality of life (QoL) and lowered rates of subsequent surgery in women who experienced persistent symptoms after uterine arteries embolization (UAE) for uterine fibroids (UF).

Major finding: Less than a fifth of the cohort underwent subsequent hysterectomy. Almost 90.9% of patients who underwent magnetic resonance imaging after 12 months of OAE showed a decrease in uterine volume and complete devascularization of the dominant fibroid tumor. After a mean follow-up of 70 months, 8 of the 10 patients who responded to the QoL questionnaire reported an improvement or stability of symptoms.

Study details: Findings are from a retrospective analysis of 1,300 women treated with UAE for symptomatic UF, of which 18 women underwent a second embolization through one or both ovarian arteries.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Ifergan H et al. Abdom Radiol (NY). 2021 Aug 25. doi: 10.1007/s00261-021-03255-w.

Key clinical point: The surgical approach for removal of uterine fibroids should consider the number and size of fibroids, surgical time, and reproductive diagnosis with minimally invasive routes offered whenever possible because of its better outcome on achieving pregnancy.

Major finding: Laparotomic myomectomy was favored when the number (P = .000) and weight (P = .004) of fibroids were considered. Robotic surgery took a longer time than others (P = .00). When the impact of number of fibroids on achieving pregnancy was analyzed, both groups with lesser (P = .017) and greater (P < .001) than 6 fibroids preferred minimally invasive routes like laparoscopic or robotic surgery.

Study details: Findings are from a retrospective, cross-sectional study including 69 patients with infertility who underwent myomectomy approaches, of which 21, 24, and 24 patients underwent laparotomy, conventional laparoscopy, and robotic-assisted laparoscopy, respectively.

Disclosures: No information on funding was available. The authors declared no conflict of interests.

Source: Morales HSG et al. JBRA Assist Reprod. 2021 Aug 20. doi: 10.5935/1518-0557.20210049.

Key clinical point: The surgical approach for removal of uterine fibroids should consider the number and size of fibroids, surgical time, and reproductive diagnosis with minimally invasive routes offered whenever possible because of its better outcome on achieving pregnancy.

Major finding: Laparotomic myomectomy was favored when the number (P = .000) and weight (P = .004) of fibroids were considered. Robotic surgery took a longer time than others (P = .00). When the impact of number of fibroids on achieving pregnancy was analyzed, both groups with lesser (P = .017) and greater (P < .001) than 6 fibroids preferred minimally invasive routes like laparoscopic or robotic surgery.

Study details: Findings are from a retrospective, cross-sectional study including 69 patients with infertility who underwent myomectomy approaches, of which 21, 24, and 24 patients underwent laparotomy, conventional laparoscopy, and robotic-assisted laparoscopy, respectively.

Disclosures: No information on funding was available. The authors declared no conflict of interests.

Source: Morales HSG et al. JBRA Assist Reprod. 2021 Aug 20. doi: 10.5935/1518-0557.20210049.

Key clinical point: The surgical approach for removal of uterine fibroids should consider the number and size of fibroids, surgical time, and reproductive diagnosis with minimally invasive routes offered whenever possible because of its better outcome on achieving pregnancy.

Major finding: Laparotomic myomectomy was favored when the number (P = .000) and weight (P = .004) of fibroids were considered. Robotic surgery took a longer time than others (P = .00). When the impact of number of fibroids on achieving pregnancy was analyzed, both groups with lesser (P = .017) and greater (P < .001) than 6 fibroids preferred minimally invasive routes like laparoscopic or robotic surgery.

Study details: Findings are from a retrospective, cross-sectional study including 69 patients with infertility who underwent myomectomy approaches, of which 21, 24, and 24 patients underwent laparotomy, conventional laparoscopy, and robotic-assisted laparoscopy, respectively.

Disclosures: No information on funding was available. The authors declared no conflict of interests.

Source: Morales HSG et al. JBRA Assist Reprod. 2021 Aug 20. doi: 10.5935/1518-0557.20210049.

Key clinical point: Uterine fibroids did not increase the risk for preterm births and were not associated with any clinical preterm birth subtype.

Major finding: Prevalence of fibroids was similar in pregnancies ending in preterm and term births (10.2% and 10.3%, respectively). Presence of fibroids was not associated with an overall risk for preterm birth (adjusted risk ratio [aRR], 0.88; 95% confidence interval [CI], 0.62-1.24) or preterm birth subtypes like medically indicated (aRR, 0.92; 95% CI, 0.43-1.96) or spontaneous (aRR, 1.27; 95% CI, 0.76-2.11) preterm births.

Study details: Findings are from a prospective cohort including 4,622 women with singleton pregnancies resulting in a live birth after 20 weeks of gestation.

Disclosures: This study was funded by National Institutes of Health, American Water Works Association Research Foundation, and the National Institute of General Medical Studies. The authors declared no conflict of interests.

Source: Sundermann AC et al. BMC Pregnancy Childbirth. 2021 Aug 17. doi: 10.1186/s12884-021-03968-2.

Key clinical point: Uterine fibroids did not increase the risk for preterm births and were not associated with any clinical preterm birth subtype.

Major finding: Prevalence of fibroids was similar in pregnancies ending in preterm and term births (10.2% and 10.3%, respectively). Presence of fibroids was not associated with an overall risk for preterm birth (adjusted risk ratio [aRR], 0.88; 95% confidence interval [CI], 0.62-1.24) or preterm birth subtypes like medically indicated (aRR, 0.92; 95% CI, 0.43-1.96) or spontaneous (aRR, 1.27; 95% CI, 0.76-2.11) preterm births.

Study details: Findings are from a prospective cohort including 4,622 women with singleton pregnancies resulting in a live birth after 20 weeks of gestation.

Disclosures: This study was funded by National Institutes of Health, American Water Works Association Research Foundation, and the National Institute of General Medical Studies. The authors declared no conflict of interests.

Source: Sundermann AC et al. BMC Pregnancy Childbirth. 2021 Aug 17. doi: 10.1186/s12884-021-03968-2.

Key clinical point: Uterine fibroids did not increase the risk for preterm births and were not associated with any clinical preterm birth subtype.

Major finding: Prevalence of fibroids was similar in pregnancies ending in preterm and term births (10.2% and 10.3%, respectively). Presence of fibroids was not associated with an overall risk for preterm birth (adjusted risk ratio [aRR], 0.88; 95% confidence interval [CI], 0.62-1.24) or preterm birth subtypes like medically indicated (aRR, 0.92; 95% CI, 0.43-1.96) or spontaneous (aRR, 1.27; 95% CI, 0.76-2.11) preterm births.

Study details: Findings are from a prospective cohort including 4,622 women with singleton pregnancies resulting in a live birth after 20 weeks of gestation.

Disclosures: This study was funded by National Institutes of Health, American Water Works Association Research Foundation, and the National Institute of General Medical Studies. The authors declared no conflict of interests.

Source: Sundermann AC et al. BMC Pregnancy Childbirth. 2021 Aug 17. doi: 10.1186/s12884-021-03968-2.

Key clinical point: The size of uterine leiomyoma commonly increases before 22-24 gestational weeks, with the growth being fastest before 11-14 weeks. The size remained almost unchanged from 22-24 weeks to the predelivery gestational weeks.

Major finding: The change in leiomyoma diameter from weeks 6-7 to 11-14, 11-14 to 22-24, 22-24 to 28-34, and 28-34 to predelivery gestational weeks was 0.767 cm, 0.367 cm, −0.133 cm, and −0.100 cm, respectively, with the difference between gestational intervals being statistically significant (P < .05). Overall, leiomyoma increased by 23.99% between weeks 6-7 to predelivery gestational weeks, with growth being highest between weeks 6-7 and 11-14 (9.92%).

Study details: Findings are from a prospective cross-sectional study including 394 pregnant women with uterine leiomyoma.

Disclosures: The study was funded by the Beijing Municipal Science & Technology Commission and Beijing Obstetrics and Gynecology Hospital. The authors declared no conflict of interests.

Source: Tian Y C et al. Int J Gynaecol Obstet. 2021 Aug 27. doi: 10.1002/ijgo.13903.

Key clinical point: The size of uterine leiomyoma commonly increases before 22-24 gestational weeks, with the growth being fastest before 11-14 weeks. The size remained almost unchanged from 22-24 weeks to the predelivery gestational weeks.

Major finding: The change in leiomyoma diameter from weeks 6-7 to 11-14, 11-14 to 22-24, 22-24 to 28-34, and 28-34 to predelivery gestational weeks was 0.767 cm, 0.367 cm, −0.133 cm, and −0.100 cm, respectively, with the difference between gestational intervals being statistically significant (P < .05). Overall, leiomyoma increased by 23.99% between weeks 6-7 to predelivery gestational weeks, with growth being highest between weeks 6-7 and 11-14 (9.92%).

Study details: Findings are from a prospective cross-sectional study including 394 pregnant women with uterine leiomyoma.

Disclosures: The study was funded by the Beijing Municipal Science & Technology Commission and Beijing Obstetrics and Gynecology Hospital. The authors declared no conflict of interests.

Source: Tian Y C et al. Int J Gynaecol Obstet. 2021 Aug 27. doi: 10.1002/ijgo.13903.

Key clinical point: The size of uterine leiomyoma commonly increases before 22-24 gestational weeks, with the growth being fastest before 11-14 weeks. The size remained almost unchanged from 22-24 weeks to the predelivery gestational weeks.

Major finding: The change in leiomyoma diameter from weeks 6-7 to 11-14, 11-14 to 22-24, 22-24 to 28-34, and 28-34 to predelivery gestational weeks was 0.767 cm, 0.367 cm, −0.133 cm, and −0.100 cm, respectively, with the difference between gestational intervals being statistically significant (P < .05). Overall, leiomyoma increased by 23.99% between weeks 6-7 to predelivery gestational weeks, with growth being highest between weeks 6-7 and 11-14 (9.92%).

Study details: Findings are from a prospective cross-sectional study including 394 pregnant women with uterine leiomyoma.

Disclosures: The study was funded by the Beijing Municipal Science & Technology Commission and Beijing Obstetrics and Gynecology Hospital. The authors declared no conflict of interests.

Source: Tian Y C et al. Int J Gynaecol Obstet. 2021 Aug 27. doi: 10.1002/ijgo.13903.

Key clinical point: Uterine fibroids (UFs) may grow continuously in some postmenopausal women, most likely because of the presence of small fibroids or obesity.

Major finding: The median growth rate of UFs was 12.9% every 6 months, with 79.5% of the UFs showing enlargement and 20.5% regressed spontaneously. The median growth rate of UFs was significantly higher in obese and overweight women than those with normal weight (P = .043). The growth was rapid in tumors with a diameter less than 3 cm vs greater than or equal to 5 cm (28.8% vs 9.1% in 6 months; P = .015).

Study details: Findings are from a retrospective longitudinal study including 102 postmenopausal women with 132 surgically identified UFs who had received at least 2 transvaginal ultrasound examinations in a 6-month interval.

Disclosures: This study was supported by the Capital Medical University Advanced Discipline Construction Project of Clinical Medicine. The authors declared no conflict of interests.

Source: Shen M et al. Menopause. 2021 Sep 6. doi: 10.1097/GME.0000000000001846.

Key clinical point: Uterine fibroids (UFs) may grow continuously in some postmenopausal women, most likely because of the presence of small fibroids or obesity.

Major finding: The median growth rate of UFs was 12.9% every 6 months, with 79.5% of the UFs showing enlargement and 20.5% regressed spontaneously. The median growth rate of UFs was significantly higher in obese and overweight women than those with normal weight (P = .043). The growth was rapid in tumors with a diameter less than 3 cm vs greater than or equal to 5 cm (28.8% vs 9.1% in 6 months; P = .015).

Study details: Findings are from a retrospective longitudinal study including 102 postmenopausal women with 132 surgically identified UFs who had received at least 2 transvaginal ultrasound examinations in a 6-month interval.

Disclosures: This study was supported by the Capital Medical University Advanced Discipline Construction Project of Clinical Medicine. The authors declared no conflict of interests.

Source: Shen M et al. Menopause. 2021 Sep 6. doi: 10.1097/GME.0000000000001846.

Key clinical point: Uterine fibroids (UFs) may grow continuously in some postmenopausal women, most likely because of the presence of small fibroids or obesity.

Major finding: The median growth rate of UFs was 12.9% every 6 months, with 79.5% of the UFs showing enlargement and 20.5% regressed spontaneously. The median growth rate of UFs was significantly higher in obese and overweight women than those with normal weight (P = .043). The growth was rapid in tumors with a diameter less than 3 cm vs greater than or equal to 5 cm (28.8% vs 9.1% in 6 months; P = .015).

Study details: Findings are from a retrospective longitudinal study including 102 postmenopausal women with 132 surgically identified UFs who had received at least 2 transvaginal ultrasound examinations in a 6-month interval.

Disclosures: This study was supported by the Capital Medical University Advanced Discipline Construction Project of Clinical Medicine. The authors declared no conflict of interests.

Source: Shen M et al. Menopause. 2021 Sep 6. doi: 10.1097/GME.0000000000001846.

Key clinical point: Women with uterine leiomyoma (UL) appeared to be at a higher risk of developing endometriosis. The risk increased further if UL was present along with comorbidities like infertility or endometritis.

Major finding: Patients with UL vs control participants were at a higher risk of developing endometriosis (adjusted hazard ratio [aHR], 6.44; P less than .001). The comorbidities significantly associated with risk for endometriosis were tube-ovarian infection (aHR, 2.86; P = .01), endometritis (aHR, 1.14; P < .001), infertility (aHR, 1.26; P <  .001), and allergic diseases (aHR, 1.11; P < .001).

Study details: Findings are from a large-scale nationwide cohort including 31,239 women with UL matched with 1,24,956 control participants and followed up for 14 years.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Lin KY et al. PLoS One. 2021 Aug 26. doi: 10.1371/journal.pone.0256772.

Key clinical point: Women with uterine leiomyoma (UL) appeared to be at a higher risk of developing endometriosis. The risk increased further if UL was present along with comorbidities like infertility or endometritis.

Major finding: Patients with UL vs control participants were at a higher risk of developing endometriosis (adjusted hazard ratio [aHR], 6.44; P less than .001). The comorbidities significantly associated with risk for endometriosis were tube-ovarian infection (aHR, 2.86; P = .01), endometritis (aHR, 1.14; P < .001), infertility (aHR, 1.26; P <  .001), and allergic diseases (aHR, 1.11; P < .001).

Study details: Findings are from a large-scale nationwide cohort including 31,239 women with UL matched with 1,24,956 control participants and followed up for 14 years.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Lin KY et al. PLoS One. 2021 Aug 26. doi: 10.1371/journal.pone.0256772.

Key clinical point: Women with uterine leiomyoma (UL) appeared to be at a higher risk of developing endometriosis. The risk increased further if UL was present along with comorbidities like infertility or endometritis.

Major finding: Patients with UL vs control participants were at a higher risk of developing endometriosis (adjusted hazard ratio [aHR], 6.44; P less than .001). The comorbidities significantly associated with risk for endometriosis were tube-ovarian infection (aHR, 2.86; P = .01), endometritis (aHR, 1.14; P < .001), infertility (aHR, 1.26; P <  .001), and allergic diseases (aHR, 1.11; P < .001).

Study details: Findings are from a large-scale nationwide cohort including 31,239 women with UL matched with 1,24,956 control participants and followed up for 14 years.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Lin KY et al. PLoS One. 2021 Aug 26. doi: 10.1371/journal.pone.0256772.

Key clinical point: Proton pump inhibitor (PPI) use was positively associated with the risk of developing psoriasis.

Major finding: Compared with PPI use of 30 or less cumulative defined daily doses (cDDD), PPI use of 120-365 (adjusted odds ratio [aOR], 1.52; 95% confidence interval [CI], 1.31-1.76) and higher than 365 (aOR, 1.54; 95% CI, 1.22-1.93) was associated with a significantly higher risk for psoriasis. Lansoprazole (OR, 1.25; 95% CI, 1.11-1.41), but not pantoprazole, esomeprazole, rabeprazole, or omeprazole, significantly contributed to psoriasis risk.

Study details: Findings are from a nationwide nested case-control study including 5,756 patients with prior exposure to PPIs, of which 2,878 patients had psoriasis.

Disclosures: The study was supported by Taipei Veterans General Hospital and Ministry of Science and Technology, Taiwan. The authors declared no potential conflict of interests.

Source: Li CY et al. Dermatology. 2021 Sep 2. doi: 10.1159/000517515.

Key clinical point: Proton pump inhibitor (PPI) use was positively associated with the risk of developing psoriasis.

Major finding: Compared with PPI use of 30 or less cumulative defined daily doses (cDDD), PPI use of 120-365 (adjusted odds ratio [aOR], 1.52; 95% confidence interval [CI], 1.31-1.76) and higher than 365 (aOR, 1.54; 95% CI, 1.22-1.93) was associated with a significantly higher risk for psoriasis. Lansoprazole (OR, 1.25; 95% CI, 1.11-1.41), but not pantoprazole, esomeprazole, rabeprazole, or omeprazole, significantly contributed to psoriasis risk.

Study details: Findings are from a nationwide nested case-control study including 5,756 patients with prior exposure to PPIs, of which 2,878 patients had psoriasis.

Disclosures: The study was supported by Taipei Veterans General Hospital and Ministry of Science and Technology, Taiwan. The authors declared no potential conflict of interests.

Source: Li CY et al. Dermatology. 2021 Sep 2. doi: 10.1159/000517515.

Key clinical point: Proton pump inhibitor (PPI) use was positively associated with the risk of developing psoriasis.

Major finding: Compared with PPI use of 30 or less cumulative defined daily doses (cDDD), PPI use of 120-365 (adjusted odds ratio [aOR], 1.52; 95% confidence interval [CI], 1.31-1.76) and higher than 365 (aOR, 1.54; 95% CI, 1.22-1.93) was associated with a significantly higher risk for psoriasis. Lansoprazole (OR, 1.25; 95% CI, 1.11-1.41), but not pantoprazole, esomeprazole, rabeprazole, or omeprazole, significantly contributed to psoriasis risk.

Study details: Findings are from a nationwide nested case-control study including 5,756 patients with prior exposure to PPIs, of which 2,878 patients had psoriasis.

Disclosures: The study was supported by Taipei Veterans General Hospital and Ministry of Science and Technology, Taiwan. The authors declared no potential conflict of interests.

Source: Li CY et al. Dermatology. 2021 Sep 2. doi: 10.1159/000517515.

Key clinical point: Patients with psoriasis displayed enhanced susceptibility to psychiatric diseases with the highest risk for those with severe psoriasis, necessitating the simultaneous treatment of both conditions.

Major finding: Patients with psoriasis were at a higher risk for depression (adjusted hazard ratio [aHR], 1.18; 95% confidence interval [CI], 1.09-1.26), anxiety disorders (aHR, 1.16; 95% CI, 1.08-1.26), and somatoform disorders (aHR, 1.21; 95% CI, 1.08-1.34) than healthy controls. Patients with moderate-to-severe vs. mild disease showed a higher risk of developing depression (aHR, 1.28; 95% CI, 1.07-1.54 vs aHR, 1.17; 95% CI, 1.07-1.27) and somatoform disorders (aHR, 1.60; 95% CI, 1.26-2.03 vs aHR, 1.13; 95% CI, 1.00-1.28).

Study details: The data come from a nationwide, prospective cohort study including 10,868 patients with psoriasis and 1,620,055 nonpsoriasis patients followed up for a maximum period of 15 years.

Disclosures: The study was sponsored by Ministry of Health and Welfare, Ministry of Science and Information and Communications Technology, Korea Centers for Disease Control and Prevention, and Ministry of Education. The authors declared no potential conflict of interests.

Source: Oh J et al. J Dermatol. 2021 Aug 30. doi: 10.1111/1346-8138.16115.

Key clinical point: Patients with psoriasis displayed enhanced susceptibility to psychiatric diseases with the highest risk for those with severe psoriasis, necessitating the simultaneous treatment of both conditions.

Major finding: Patients with psoriasis were at a higher risk for depression (adjusted hazard ratio [aHR], 1.18; 95% confidence interval [CI], 1.09-1.26), anxiety disorders (aHR, 1.16; 95% CI, 1.08-1.26), and somatoform disorders (aHR, 1.21; 95% CI, 1.08-1.34) than healthy controls. Patients with moderate-to-severe vs. mild disease showed a higher risk of developing depression (aHR, 1.28; 95% CI, 1.07-1.54 vs aHR, 1.17; 95% CI, 1.07-1.27) and somatoform disorders (aHR, 1.60; 95% CI, 1.26-2.03 vs aHR, 1.13; 95% CI, 1.00-1.28).

Study details: The data come from a nationwide, prospective cohort study including 10,868 patients with psoriasis and 1,620,055 nonpsoriasis patients followed up for a maximum period of 15 years.

Disclosures: The study was sponsored by Ministry of Health and Welfare, Ministry of Science and Information and Communications Technology, Korea Centers for Disease Control and Prevention, and Ministry of Education. The authors declared no potential conflict of interests.

Source: Oh J et al. J Dermatol. 2021 Aug 30. doi: 10.1111/1346-8138.16115.

Key clinical point: Patients with psoriasis displayed enhanced susceptibility to psychiatric diseases with the highest risk for those with severe psoriasis, necessitating the simultaneous treatment of both conditions.

Major finding: Patients with psoriasis were at a higher risk for depression (adjusted hazard ratio [aHR], 1.18; 95% confidence interval [CI], 1.09-1.26), anxiety disorders (aHR, 1.16; 95% CI, 1.08-1.26), and somatoform disorders (aHR, 1.21; 95% CI, 1.08-1.34) than healthy controls. Patients with moderate-to-severe vs. mild disease showed a higher risk of developing depression (aHR, 1.28; 95% CI, 1.07-1.54 vs aHR, 1.17; 95% CI, 1.07-1.27) and somatoform disorders (aHR, 1.60; 95% CI, 1.26-2.03 vs aHR, 1.13; 95% CI, 1.00-1.28).

Study details: The data come from a nationwide, prospective cohort study including 10,868 patients with psoriasis and 1,620,055 nonpsoriasis patients followed up for a maximum period of 15 years.

Disclosures: The study was sponsored by Ministry of Health and Welfare, Ministry of Science and Information and Communications Technology, Korea Centers for Disease Control and Prevention, and Ministry of Education. The authors declared no potential conflict of interests.

Source: Oh J et al. J Dermatol. 2021 Aug 30. doi: 10.1111/1346-8138.16115.

Key clinical point: Secukinumab caused substantial and sustained skin clearance irrespective of prior treatment, leading to high patient satisfaction in patients with moderate-to-severe plaque psoriasis.

Major finding: Overall, 82.3% of patients endorsed the skin clearing effect of secukinumab at 6 months, which persisted through 12 (81.7%), 18 (83.3%), and 24 (81.4%) months. Biologic-experienced/naive and systemic-experienced/naive patients showed similar results. Of those dissatisfied at baseline, 77.9% of patients reported satisfaction at 6 months, which lasted through 12 (74.4%), 18 (82.8%), and 24 (71.4%) months.

Study details: The study included 3,680 patients aged 18 years or above with moderate-to-severe plaque psoriasis who received secukinumab.

Disclosures: The study was supported by Novartis Pharmaceuticals Corporation, East Hanover, NJ. AW Armstrong and PS Yamauchi declared serving as an investigator/consultant/advisor/speaker for various organizations. D Patil, E Levi, and E Nguyen declared being employees of Novartis Pharmaceuticals Corporation.

Source: Armstrong AW et al. Dermatol Ther (Heidelb). 2021 Aug 28. doi: 10.1007/s13555-021-00599-5.

Key clinical point: Secukinumab caused substantial and sustained skin clearance irrespective of prior treatment, leading to high patient satisfaction in patients with moderate-to-severe plaque psoriasis.

Major finding: Overall, 82.3% of patients endorsed the skin clearing effect of secukinumab at 6 months, which persisted through 12 (81.7%), 18 (83.3%), and 24 (81.4%) months. Biologic-experienced/naive and systemic-experienced/naive patients showed similar results. Of those dissatisfied at baseline, 77.9% of patients reported satisfaction at 6 months, which lasted through 12 (74.4%), 18 (82.8%), and 24 (71.4%) months.

Study details: The study included 3,680 patients aged 18 years or above with moderate-to-severe plaque psoriasis who received secukinumab.

Disclosures: The study was supported by Novartis Pharmaceuticals Corporation, East Hanover, NJ. AW Armstrong and PS Yamauchi declared serving as an investigator/consultant/advisor/speaker for various organizations. D Patil, E Levi, and E Nguyen declared being employees of Novartis Pharmaceuticals Corporation.

Source: Armstrong AW et al. Dermatol Ther (Heidelb). 2021 Aug 28. doi: 10.1007/s13555-021-00599-5.

Key clinical point: Secukinumab caused substantial and sustained skin clearance irrespective of prior treatment, leading to high patient satisfaction in patients with moderate-to-severe plaque psoriasis.

Major finding: Overall, 82.3% of patients endorsed the skin clearing effect of secukinumab at 6 months, which persisted through 12 (81.7%), 18 (83.3%), and 24 (81.4%) months. Biologic-experienced/naive and systemic-experienced/naive patients showed similar results. Of those dissatisfied at baseline, 77.9% of patients reported satisfaction at 6 months, which lasted through 12 (74.4%), 18 (82.8%), and 24 (71.4%) months.

Study details: The study included 3,680 patients aged 18 years or above with moderate-to-severe plaque psoriasis who received secukinumab.

Disclosures: The study was supported by Novartis Pharmaceuticals Corporation, East Hanover, NJ. AW Armstrong and PS Yamauchi declared serving as an investigator/consultant/advisor/speaker for various organizations. D Patil, E Levi, and E Nguyen declared being employees of Novartis Pharmaceuticals Corporation.

Source: Armstrong AW et al. Dermatol Ther (Heidelb). 2021 Aug 28. doi: 10.1007/s13555-021-00599-5.

Key clinical point: For a certain body mass index (BMI), abdominal subcutaneous adipose tissue (ASAT) was negatively associated with coronary atherosclerosis burden in men with psoriasis.

Major finding: After adjusting for traditional risk factors and each patient's BMI, ASAT was negatively associated with noncalcified and lipid-rich necrotic core burden in men (β, −0.17; P = .03; β, −0.20; P = .03, respectively) but not in women (β, −0.06; P = .57; β, 0.09; P = .49, respectively) with psoriasis.

Study details: The data come from a cross-sectional study of 232 patients with psoriasis and without known cardiovascular disease, of which 92 were women.

Disclosures: The study was supported by National Heart, Lung, and Blood Institute Intramural Research Program (Bethesda, Maryland). Dr. Mehta declared being a current full-time U.S. government employee and receiving a research grant from various sources. Dr. Khera declared serving as a scientific advisor and receiving speaker fees from various sources.

Source: Teklu M et al. Am J Prev Cardiol. 2021 Aug 22. doi: 10.1016/j.ajpc.2021.100231.

Key clinical point: For a certain body mass index (BMI), abdominal subcutaneous adipose tissue (ASAT) was negatively associated with coronary atherosclerosis burden in men with psoriasis.

Major finding: After adjusting for traditional risk factors and each patient's BMI, ASAT was negatively associated with noncalcified and lipid-rich necrotic core burden in men (β, −0.17; P = .03; β, −0.20; P = .03, respectively) but not in women (β, −0.06; P = .57; β, 0.09; P = .49, respectively) with psoriasis.

Study details: The data come from a cross-sectional study of 232 patients with psoriasis and without known cardiovascular disease, of which 92 were women.

Disclosures: The study was supported by National Heart, Lung, and Blood Institute Intramural Research Program (Bethesda, Maryland). Dr. Mehta declared being a current full-time U.S. government employee and receiving a research grant from various sources. Dr. Khera declared serving as a scientific advisor and receiving speaker fees from various sources.

Source: Teklu M et al. Am J Prev Cardiol. 2021 Aug 22. doi: 10.1016/j.ajpc.2021.100231.

Key clinical point: For a certain body mass index (BMI), abdominal subcutaneous adipose tissue (ASAT) was negatively associated with coronary atherosclerosis burden in men with psoriasis.

Major finding: After adjusting for traditional risk factors and each patient's BMI, ASAT was negatively associated with noncalcified and lipid-rich necrotic core burden in men (β, −0.17; P = .03; β, −0.20; P = .03, respectively) but not in women (β, −0.06; P = .57; β, 0.09; P = .49, respectively) with psoriasis.

Study details: The data come from a cross-sectional study of 232 patients with psoriasis and without known cardiovascular disease, of which 92 were women.

Disclosures: The study was supported by National Heart, Lung, and Blood Institute Intramural Research Program (Bethesda, Maryland). Dr. Mehta declared being a current full-time U.S. government employee and receiving a research grant from various sources. Dr. Khera declared serving as a scientific advisor and receiving speaker fees from various sources.

Source: Teklu M et al. Am J Prev Cardiol. 2021 Aug 22. doi: 10.1016/j.ajpc.2021.100231.